HIGHLIGHT14 September 2017
- Represented a global solid state LED lighting and semiconductor manufacturing company in connection with its $850 million sale of a manufacturing division.
- Advised a leading video game company in the sale of a game franchise to a global computer software company and assisted in the development of an innovative licensing model for the client's video game development software.
- Prepared a negotiation “toolkit” establishing contracting parameters and fallback positions to allocate and address intellectual property and data-related risks in a global technology company’s software-as-a-service and data hosting arrangements.
- Assisted a leading corporate travel management firm in the U.S. with drafting and negotiation of a services agreement with a creative consulting firm for a brand identity refresh and related website redesign and development services.
- Representation of a leading provider of wireless transmission systems in its divestiture of an integrated communications network management software platform and related assets to a network management software company.
- Assisted an e-commerce vendor in developing terms of use, privacy policy and consignment and sale agreements for use in an online business.
- Represented a leading fuel pump supplier in establishing a technology, sales and service partnership with a leading payment system supplier to develop next-generation payment and media technologies for the retail petroleum industry.
- Conducted training sessions for the legal department of one of the world’s largest software and technology service providers, providing negotiation and risk allocation strategies for the company’s technology license and services arrangements, covering complex indemnity provisions, license provisions and related risk allocation issues.
- Lead counsel to a venture capital-funded genome editing company in a worldwide partnership, worth up to $1.6 billion, including an upfront payment of $105 million, with a global, publicly-traded pharmaceutical company to develop and commercialize allogeneic chimeric antigen receptor (CAR) T cell therapies for multiple cancers. The transaction was awarded the 2016 Life Science sector Deals of Distinction™ award by the Licensing Executives Society.
- Represented an international health care group and its U.S. specialty pharmaceutical company subsidiary in obtaining multinational license rights to three cardiovascular drugs from a large public pharmaceutical company for $264 million in cash at closing, up to $480 million in milestone and royalty payments, and the assumption of up to $50 million in milestone payment obligations.
- Over 100 AgTech research, development, license and collaboration agreements, totaling in excess of $550 million in cumulative value plus royalties, including over 30 transactions involving five of the six largest agriculture companies in the world.
- Represented a venture capital-funded biotechnology company that uses the plant-associated microbiome to create innovative agricultural products in an R&D collaboration with a leading global agricultural biotechnology company for discovery, development and commercialization of crop trait products.
- Represented a leading genome editing company in over a dozen research, collaboration, licensing and development agreements ranging from human therapeutics to row plant crop applications and specialty plant crop applications.
- Represented university spin-outs in licensing foundational technology from universities such as Harvard University/Massachusetts General Hospital, Columbia University, Duke University, Johns Hopkins University, University of California at San Francisco, Duquesne University, University of North Carolina at Chapel Hill, North Carolina State University, East Carolina University, Dartmouth College, University of Pennsylvania, University of Virginia and Virginia Tech
- Dozens of worldwide and territory-specific pharmaceutical, biologic and medical device research, development, license, collaboration and acquisition agreements, for therapeutic areas ranging from immuno-oncology to CNS disorders, dermatology, ophthalmology, cardiovascular, rare disease, oncology, vaccines, and others.